Literature DB >> 8900437

Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells.

T Frisan1, Q J Zhang, J Levitskaya, M Coram, M G Kurilla, M G Masucci.   

Abstract

Defects of antigen processing/presentation have been suggested to play a role in the escape of Burkitt's lymphoma (BL) from cytotoxic T lymphocyte (CTL)-mediated rejection. Impaired presentation of an immunodominant HLA A11-restricted epitope from the resident or recombinant vaccinia virus-expressed Epstein-Barr virus nuclear antigen (EBNA)4 was demonstrated in the EBV-positive E95B-BL28 and its EBV-negative parental BL28 cell lines. We have investigated whether this was due to (i) impaired production of the antigenic peptide, (ii) poor peptide translocation into the ER lumen or (iii) inefficient maturation and transport of the MHC-peptide complexes at the cell surface. The defect was not overcome by cytosolic expression of a pre-formed epitope, suggesting that presentation of EBNA4 is not limited by inefficient production of the antigenic peptide. BL28 expressed 5- to 10-fold lower levels of the transporter associated with antigen presentation (TAP) 1 and TAP2 proteins and behaved poorly in a streptolysin-O-mediated peptide translocation assay, whereas E95B-BL28 showed higher TAP expression and virtually normal transporter function. Up-regulation of HLA A11 and reconstitution of TAP activity by treatment with IFN-gamma did not restore presentation of the resident EBNA4 in E95SB-BL28 and did not enhance presentation of the vaccinia virus-expressed intact protein or preformed epitope. Efficient maturation of class I molecules to Endo H-resistant species was demonstrated in pulse-chase experiments. Taken together, our findings identify a previously uncharacterized defect of antigen presentation which appears to affect events occurring after proteasomal degradation but before TAP-dependent peptide transport and MHC class I assembly and maturation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8900437     DOI: 10.1002/(SICI)1097-0215(19961009)68:2<251::AID-IJC19>3.0.CO;2-D

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.

Authors:  Martin S Staege; Steven P Lee; Teresa Frisan; Josef Mautner; Siegfried Scholz; Alexander Pajic; Alan B Rickinson; Maria G Masucci; Axel Polack; Georg W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

2.  Immune escape mechanisms in ALCL.

Authors:  J J Oudejans; R L ten Berge; C J L M Meijer
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

3.  Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Lisa M Rimsza; Michael L Leblanc; Joseph M Unger; Thomas P Miller; Thomas M Grogan; Daniel O Persky; Ralph R Martel; Constantine M Sabalos; Bruce Seligmann; Rita M Braziel; Elias Campo; Andreas Rosenwald; Joseph M Connors; Laurie H Sehn; Nathalie Johnson; Randy D Gascoyne
Journal:  Blood       Date:  2008-06-10       Impact factor: 22.113

4.  Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.

Authors:  Federica Destro; Fabio Sforza; Mariaconcetta Sicurella; Diego Marescotti; Eleonora Gallerani; Anna Baldisserotto; Mauro Marastoni; Riccardo Gavioli
Journal:  Immunology       Date:  2011-02-22       Impact factor: 7.397

5.  Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition.

Authors:  Jason M God; Dan Zhao; Christine A Cameron; Shereen Amria; Jennifer R Bethard; Azizul Haque
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

Review 6.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Blood Adv       Date:  2017-12-08

Review 7.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

8.  Kinetic analysis of the specific host response to a murine gammaherpesvirus.

Authors:  P G Stevenson; P C Doherty
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

9.  Inhibition of heavy chain and beta2-microglobulin synthesis as a mechanism of major histocompatibility complex class I downregulation during Epstein-Barr virus replication.

Authors:  Andre Ortlieb Guerreiro-Cacais; Mehmet Uzunel; Jelena Levitskaya; Victor Levitsky
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

10.  Differential Recognition of Influenza A Viruses by M158-66 Epitope-Specific CD8+ T Cells Is Determined by Extraepitopic Amino Acid Residues.

Authors:  Carolien E van de Sandt; Joost H C M Kreijtz; Martina M Geelhoed-Mieras; Nella J Nieuwkoop; Monique I Spronken; David A M C van de Vijver; Ron A M Fouchier; Albert D M E Osterhaus; Guus F Rimmelzwaan
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.